



Corrigendum

Corrigendum to “HIV-1 Tat protein attenuates the clinical course of experimental autoimmune encephalomyelitis (EAE)” [Int. Immunopharmacol. 78 (2020) 105943]

Sajad Karampoor^a, Hamid Zahednasab^b, Farah Bokharaei-Salim^a, Rasoul Mirzaei^c, Zahra Mojallal-Tabatabaei^b, Maryam Esghaeia^{a,*}, Hossein Keyvani^{a,*}

^a Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

^b Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran

^c Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran



The authors regret to inform that there was an inadvertent error in the section of “2.1. Experimental autoimmune encephalomyelitis (EAE) induction” and the correct text is provided below:

Ten-week-old female C57BL/6 mice were purchased from the Pasteur Institute (Tehran, Iran). All animals were kept in a sterile facility according to the Guidelines of the Iran University of Medical Science. All animal procedures were in accordance with the Ethics Committee of the Iran University of Medical Science (IR.IUMS.FMD.REC 1396.9321540002). The EAE model was provided by “Salari Institute of Cognitive and Behavioral Disorders (SICBD)”. To this aim, the animals were anesthetized by the intraperitoneal

administration of ketamine and xylazine. Then, 300 µg of Myelin Oligodendrocyte Glycoprotein (MOG35–55; SICBD) peptide was emulsified with complete Freund's adjuvant (500 µg *Mycobacterium tuberculosis*; CFA; Sigma, F5881, USA) and subcutaneously injected into both hind flanks of each mouse. All mice received two doses of 0.3 µg pertussis toxin (List Biological Lab, Campbell, CA, USA) through the intraperitoneal (i.p.) injection about two hours and forty-eight hours after immunization.

All authors are aware of the errors and have agreed to the correction. The authors would also like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.intimp.2019.105943>

* Corresponding authors.

E-mail addresses: maryam.esghaei@gmail.com (M. Esghaeia), keyvanlab@yahoo.com (H. Keyvani).

<https://doi.org/10.1016/j.intimp.2020.106742>